Galena Biopharma to Report First Quarter Financial Results on Thursday, May 7, 2015
April 23 2015 - 7:05AM
Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company
developing and commercializing innovative, targeted oncology
therapeutics that address major medical needs across the full
spectrum of cancer care, today announced that the Company will
report its first quarter 2015 financial results on Thursday, May 7,
2015 after the close of the financial markets. The company will
host a webcast and conference call following the announcement at
2:00 p.m. P.T./5:00 p.m. E.T. to discuss the financial and business
results.
The live webcast will include slides that can be accessed on the
Company's website under the Investors section/Events and
Presentations: http://investors.galenabiopharma.com/events.cfm. The
conference call can be accessed by dialing (844) 825-4413 toll-free
in the U.S., or (973) 638-3403 for participants outside the U.S.
The Conference ID number is: 33786642. The archived webcast replay
will be available on the Company's website for 90 days.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq:GALE) is a biopharmaceutical
company developing and commercializing innovative, targeted
oncology therapeutics that address major medical needs across the
full spectrum of cancer care. Galena's development portfolio ranges
from mid- to late-stage clinical assets, including a robust
immunotherapy program led by NeuVax™ (nelipepimut-S) currently in
an international, Phase 3 clinical trial. The Company's commercial
drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz®
(ondansetron) Oral Soluble Film. Collectively, Galena's clinical
and commercial strategy focuses on identifying and advancing
therapeutic opportunities to improve cancer care, from direct
treatment of the disease to the reduction of its debilitating
side-effects. For more information, visit
www.galenabiopharma.com.
CONTACT: Remy Bernarda
SVP, Investor Relations & Corporate Communications
(503) 405-8258
rbernarda@galenabiopharma.com
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024